QCPN
... category for MALDI. It is based on an orthogonal ...SCIEX joint venture from the University of Manitob...rometer with an orthogonal design and collisional ...leap forward from conventional MALDI-TOF in mass a...
Rat Aortic Endothelial Cells (RAOEC) (>500,000 cells)
... with a wide range of solvents, from volatile orga...er boiling point solvents. ,A centrifugal con...lvents from a variety of sample formats including ... making it an ideal "work-horse" concentrator for ...
Biology Products:(Date:12/3/2008)...ing a harmless virus to insert a corrective gene i...dren,s Research Hospital have alleviated sickle ce...chers found that the treated mice showed essential...ientists caution that applying the gene therapy to...they believe that the new therapy will become an i...
(Date:12/3/2008)...e widespread problem of children failing to take t...lnesses is to be tackled as part of a new universi...ing health specialists at The University of Nottin...the experiences of school children with asthma, di...earn about the barriers that prevent them from tak...
(Date:12/3/2008)...sed on the outstanding success of the first tandem...has paired the two satellites together again to he...S-2, ESA,s veteran spacecraft, and Envisat, the la...ry Synthetic Aperture Radar (SAR) instruments that...face. ,By combining two or more SAR images of t...
(Date:12/3/2008)...erfield, IL, December 3, 2008 Today, the Internat...world,s leading professional organization of stem ...responsible development of safe and effective stem... that summarizes the Guidelines for the Clinical T... Press in the December issue of Cell Stem Cell , ...
Breaking Biology News(10 mins):Gene therapy corrects sickle cell disease in laboratory study 2Gene therapy corrects sickle cell disease in laboratory study 3A spoonful of sugar? 2A spoonful of sugar? 3ESA satellites flying in formation 2The International Society for Stem Cell Research releases new guidelines 2The International Society for Stem Cell Research releases new guidelines 3Landmark study opens door to new cancer aging treatments 4657 1Landmark study opens door to new cancer aging treatments 4657 2Landmark study opens door to new cancer aging treatments 4657 3TRANSCEND 28TM 29 Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 2912 1TRANSCEND 28TM 29 Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 2912 2TRANSCEND 28TM 29 Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 2912 3TRANSCEND 28TM 29 Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 2912 4TRANSCEND 28TM 29 Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 2912 5TRANSCEND 28TM 29 Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 2912 6TRANSCEND 28TM 29 Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 2912 7Global study shows telmisartan reduces outcome of cardiovascular death heart attack or stroke 25904 1Global study shows telmisartan reduces outcome of cardiovascular death heart attack or stroke 25904 2Antioxidant Rich Diet May Protect Against Eye Disease 25899 1Antioxidant Rich Diet May Protect Against Eye Disease 25899 2(Date:12/3/2008)... GlaxoSmithKline,(LSE/N...condition relating to a,pending lawsuit in the pr...,the outstanding shares of common stock of Genela...0 per share in cash without interest and less any,...ition to the completion of the tender offer that t...
(Date:12/3/2008)...stCall/ -- Advanced Life Sciences Holdings,Inc. ...ood and Drug,Administration (FDA) has accepted an...for cethromycin, a novel once-a-day oral antibioti...y acquired pneumonia (CAP). The FDA has,establis... the anticipated,target action date of the cethro...
(Date:12/3/2008)...swire-FirstCall/ -- AstraZeneca (NYSE: AZN ),to...ice President and Chief,Financial Officer of Astr...ponsible for all Finance and Information Services,...09. He will be a member of,the US Leadership Tea...eneca,US. , In announcing Baker,s appointm...
(Date:12/3/2008)...c. 3 Rigel,Pharmaceutic...embers of Rigel,s,senior management team will hos...Sunday, December 7, 2008, at 4:00 p.m. PST, to dis...l of R788, an oral Syk kinase inhibitor, in,patie...Conference Call and Webcast Information , T...
Breaking Biology Technology:GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 3Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia 2Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia 3AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America 2Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH 2...sker Bhattacherjee, Partha Mukhopadhyay, Saurabh S...ersity of Louisville Birth Defects Center, Departm...y, Louisville, KY 40202 , , Abstract ,...e Microdissection (LCM) method for the isolation o...ein (EGFP) from frozen sections of embryonic tissu...
..., Abstract , This application note describe...from rodent tissues that have been fixed in formal...plification of mRNA from these tissues for use in ...ogy to demonstrate that robust and reliable method...cids from formalin-fixed, paraffin-embedded (FFPE)...
..., , Modern technologies developed in recent ... support biomedical research. The ability to study...genomic material to detect genetic disordersmade p...ePlex whole-genome amplification (WGA) systemis ... high-throughput genomics and DNA sequencing has p...
... , Key words: α 2c rece... • LEADseeker • SPA Imaging Beads ,...ors are G protein-coupled receptors that play a ke...nctions such as renal Na + re-absorption, insulin...tter release at sympathetic nerve endings (1). The...
Other Biology Technology:Laser Capture Microdissection of Cells Labeled with Enhanced Green Fluorescent Protein 2Laser Capture Microdissection of Cells Labeled with Enhanced Green Fluorescent Protein 3Laser Capture Microdissection of Cells Labeled with Enhanced Green Fluorescent Protein 4Laser Capture Microdissection of Cells Labeled with Enhanced Green Fluorescent Protein 5A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays 2A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays 3A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays 4A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays 5A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays 6A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays 7A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays 8A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays 9Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies 2Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies 3Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System 2Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System 3Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System 4